Capecitabine‑induced hand‑foot syndrome does not emerge in the complex regional pain syndrome‑affected limb: A case report

Inoue,Reo; Abe,Hiroaki; Konishi,Mitsuru; Tsuchida,Rikuhei; Edamura,Tatsuma; Sumitani,Masahiko

doi:10.3892/mco.2021.2416

Capecitabine‑induced hand‑foot syndrome does not emerge in the complex regional pain syndrome‑affected limb: A case report

Authors:
- Reo Inoue
- Hiroaki Abe
- Mitsuru Konishi
- Rikuhei Tsuchida
- Tatsuma Edamura
- Masahiko Sumitani
View Affiliations

Affiliations: Anesthesiology and Pain Relief Centre, The University of Tokyo Hospital, Tokyo 113‑0033, Japan, Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo 113‑0033, Japan, Department of Pain and Palliative Medical Sciences, Faculty of Medicine, The University of Tokyo Hospital, Tokyo 113‑0033, Japan
Published online on: October 8, 2021 https://doi.org/10.3892/mco.2021.2416
Article Number: 254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hand‑foot syndrome (HFS) is a frequent adverse effect of various anti‑tumour drugs, such as capecitabine, that affects their dose‑limiting toxicity. The mechanism of HFS remains unknown and there are currently no effective strategies to treat HFS, except for cessation. The current study presented a female case where one hand, affected by brachial plexus infiltration due to the subclavian lymph node metastasis of breast cancer, exhibited not only pain and partial motor paralysis but also anhidrosis, oedema and skin colour changes. The patient met the diagnostic criteria for complex regional pain syndrome (CRPS). After treatment with capecitabine, their anhidrosis hand completely prevented HFS. The other hand and both feet demonstrated typical symptoms of HFS, which improved consequent to capecitabine cessation. The CRPS‑affected hand remained normal. Considering the limited presentation of HFS concomitant with anhidrosis, the exocrine release of condensed capecitabine through sweat glands might be a promising mechanism of HFS induction.

View Figures

View References

1	Zuehlke RL: Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 148:90–92. 1974.PubMed/NCBI View Article : Google Scholar
2	Miller KK, Gorcey L and McLellan BN: Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 71:787–794. 2014.PubMed/NCBI View Article : Google Scholar
3	Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005.PubMed/NCBI View Article : Google Scholar
4	Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK and Kang YK: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol. 44:1166–1172. 2004.PubMed/NCBI View Article : Google Scholar
5	Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, Suenaga M, Mizunuma N, Yamaguchi T and Hama T: Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother. 49:1120–1124. 2015.PubMed/NCBI View Article : Google Scholar
6	Macedo LT, Lima JP, dos Santos LV and Sasse AD: Prevention strategies for chemotherapy-induced hand-foot syndrome: A systematic review and meta-analysis of prospective randomized trials. Support Care Cancer. 22:1585–1593. 2014.PubMed/NCBI View Article : Google Scholar
7	Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, Li G, Zhu H, Yang B, Luo P and He Q: The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol. 49:81–88. 2017.PubMed/NCBI View Article : Google Scholar
8	Martschick A, Sehouli J, Patzelt A, Richter H, Jacobi U, Oskay-Ozcelik G, Sterry W and Lademann J: The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 29:2307–2313. 2009.PubMed/NCBI
9	Saif MW, Elfiky A and Diasio R: Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer. 6:219–223. 2006.PubMed/NCBI View Article : Google Scholar
10	Hoesly FJ, Baker SG, Gunawardane ND and Cotliar JA: Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: Case report and review of the literature. Arch Dermatol. 147:1418–1423. 2011.PubMed/NCBI View Article : Google Scholar
11	Lin E, Morris JS and Ayers GD: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park). 16 (Suppl 14):S31–S37. 2002.PubMed/NCBI
12	Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ and Chen G: Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: Result of a single-center, prospective randomized phase III trial. Ann Oncol. 23:1348–1353. 2012.PubMed/NCBI View Article : Google Scholar
13	Petersen PB, Mikkelsen KL, Lauritzen JB and Krogsgaard MR: Risk factors for post-treatment complex regional pain syndrome (CRPS): An analysis of 647 cases of CRPS from the Danish patient compensation association. Pain Pract. 18:341–349. 2018.PubMed/NCBI View Article : Google Scholar
14	Galer BS, Bruehl S and Harden RN: IASP diagnostic criteria for complex regional pain syndrome: A preliminary empirical validation study. International association for the study of pain. Clin J Pain. 14:48–54. 1998.PubMed/NCBI View Article : Google Scholar
15	Sumitani M, Shibata M, Sakaue G and Mashimo M: Japanese CRPS Research Group. Development of comprehensive diagnostic criteria for complex regional pain syndrome in the Japanese population. Pain. 150:243–249. 2010.PubMed/NCBI View Article : Google Scholar
16	Almeida da Cruz L, Hoff PM, Ferrari CL and Riechelmann RS: Unilateral hand-foot syndrome: Does it take sides? Case report and literature review. Clin Colorectal Cancer. 11:82–84. 2012.PubMed/NCBI View Article : Google Scholar
17	Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O and Saif MW: Unilateral hand-foot syndrome: An extraordinary side effect of capecitabine. Cutan Ocul Toxicol. 29:140–142. 2010.PubMed/NCBI View Article : Google Scholar
18	Matsuda S, Koketsu H, Hayakawa M and Nagata N: Unilateral capecitabine-related hand-foot syndrome. Intern Med. 54(2779)2015.PubMed/NCBI View Article : Google Scholar
19	Huang MD, Fuss H, Lademann J, Florek S, Patzelt A, Meinke MC and Jung S: Detection of capecitabine (Xeloda®) on the skin surface after oral administration. J Biomed Opt. 21(47002)2016.PubMed/NCBI View Article : Google Scholar